Abstract
The risk for congestive heart failure (CHF) in breast cancer patients using trastuzumab has been carefully documented. To evaluate this cardiac effect on a population level, investigators conducted a retrospective cohort study of 19,074 women identified in the Ontario Cancer Registry who received adjuvant chemotherapy for stage I–III breast cancer between 2003 and 2009. Of these patients, 15,703 (82.3%) received chemotherapy alone …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
